Literature DB >> 9253510

An HSVtk-mediated local and distant antitumor bystander effect in tumors of head and neck origin in athymic mice.

W Bi1, Y G Kim, E S Feliciano, L Pavelic, K M Wilson, Z P Pavelic, P J Stambrook.   

Abstract

The "bystander effect," produced by ganciclovir-mediated killing of cells transduced with a herpes simplex virus thymidine kinase (HSVtk) gene, defines the cooperative killing of non-HSVtk-transduced cells. In vitro, a major contributor to this phenomenon is metabolic cooperation involving transfer of cytotoxic small molecules between cells via gap junctions. In this study, the bystander effect was assessed in vivo using cells of oral squamous cell carcinoma origin. Mixtures of HSVtk+ and HSVtk- tumor cells were implanted subcutaneously in the left flank of nude mice, and naive HSVtk- cells were implanted subcutaneously in the right flank. When tumors attained a size of 0.5 to 1 cm, the animals were treated with ganciclovir on a daily basis. The tumors comprised of mixed cells in the left flank resolved, consistent with a predicted bystander effect. The naive tumors in the right flank either resolved or became cytostatic showing little further growth compared to controls. Similar results were obtained when naive tumors were grown in both flanks and the tumor in the left flank received intratumoral injection of HSVtk retroviral producer cells or PA317 (HSVtk+) packaging cells, but not parental NIH 3T3 cells. Concomitant treatment with dexamethasone impaired the antitumor effect on the contralateral side. When these experiments were performed in SCID-Beige mice, there was a reduced antitumor effect on the ipsilateral flank and no antitumor response in the contralateral flank. Together with histology of regressing tumors, which showed an infiltration of lymphoid cells, these results are suggestive of an immune-related antitumor response that could account for the distant bystander effect.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9253510

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN: 0929-1903            Impact factor:   5.987


  11 in total

1.  Replication-competent herpes simplex virus vector G207 and cisplatin combination therapy for head and neck squamous cell carcinoma.

Authors:  A Chahlavi; T Todo; R L Martuza; S D Rabkin
Journal:  Neoplasia       Date:  1999-06       Impact factor: 5.715

2.  Cancer gene therapy: combination with radiation therapy and the role of bystander cell killing in the anti-tumor effect.

Authors:  Katalin Lumniczky; Géza Sáfrány
Journal:  Pathol Oncol Res       Date:  2006-06-24       Impact factor: 3.201

Review 3.  Gene-directed enzyme prodrug therapy.

Authors:  Jin Zhang; Vijay Kale; Mingnan Chen
Journal:  AAPS J       Date:  2014-10-23       Impact factor: 4.009

Review 4.  Gene therapy and targeted toxins for glioma.

Authors:  Maria G Castro; Marianela Candolfi; Kurt Kroeger; Gwendalyn D King; James F Curtin; Kader Yagiz; Yohei Mineharu; Hikmat Assi; Mia Wibowo; A K M Ghulam Muhammad; David Foulad; Mariana Puntel; Pedro R Lowenstein
Journal:  Curr Gene Ther       Date:  2011-06       Impact factor: 4.391

Review 5.  Gene therapy and targeted toxins for glioma.

Authors:  Gwendalyn D King; James F Curtin; Marianela Candolfi; Kurt Kroeger; Pedro R Lowenstein; Maria G Castro
Journal:  Curr Gene Ther       Date:  2005-12       Impact factor: 4.391

6.  Subcutaneous or intrahepatic injection of suicide gene modified tumour cells induces a systemic antitumour response in a metastatic model of colon carcinoma in rats.

Authors:  V Pierrefite-Carle; P Baqué; A Gavelli; N Brossette; D Benchimol; A Bourgeon; M C Saint Paul; P Staccini; B Rossi
Journal:  Gut       Date:  2002-03       Impact factor: 23.059

7.  Suicide Gene Therapy for Cancer - Current Strategies.

Authors:  Paul Zarogoulidis; Kaid Darwiche; Antonios Sakkas; Lonny Yarmus; Haidong Huang; Qiang Li; Lutz Freitag; Konstantinos Zarogoulidis; Marek Malecki
Journal:  J Genet Syndr Gene Ther       Date:  2013-08-09

8.  Flt3L and TK gene therapy eradicate multifocal glioma in a syngeneic glioblastoma model.

Authors:  Gwendalyn D King; A K M Ghulam Muhammad; James F Curtin; Carlos Barcia; Mariana Puntel; Chunyan Liu; Sarah B Honig; Marianela Candolfi; Sonali Mondkar; Pedro R Lowenstein; Maria G Castro
Journal:  Neuro Oncol       Date:  2007-12-13       Impact factor: 12.300

Review 9.  The current state of head and neck cancer gene therapy.

Authors:  Sufi Mary Thomas; Jennifer Rubin Grandis
Journal:  Hum Gene Ther       Date:  2009-12       Impact factor: 5.695

10.  A dual function fusion protein of Herpes simplex virus type 1 thymidine kinase and firefly luciferase for noninvasive in vivo imaging of gene therapy in malignant glioma.

Authors:  Ariane Söling; Christian Theiss; Stephanie Jungmichel; Nikolai G Rainov
Journal:  Genet Vaccines Ther       Date:  2004-08-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.